ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25nov1009

The Impact of Digital Strategies on Pharmaceutical Marketing Consumer Behavior, Ethics, and Compliance

Deepshikha Singh[1]

[1]Student, Department of MBA, IIM JAMMU, Jammu, Jammu and Kashmir India

[1](ORCID ID: 0009-0002-4603-0830)

Publication Date: 2025/12/03

Abstract: Pharmaceutical marketing occupies a contentious space between commercial objectives and public-health responsibility as the industry rapidly adopts digital technologies. Digital platforms enable precise outreach and patient engagement but also amplify ethical risks such as covert promotion, misinformation, and privacy breaches. Direct-to-consumer promotion influences patient requests and prescribing behaviour, with measurable impacts on medicine use and clinician–patient interactions. Regulatory activity has responded variably: recent U.S. initiatives emphasise clearer disclosure and oversight of online and influencer-driven promotion, while international approaches remain heterogeneous. In India, formal guidance exists yet enforcement gaps and limited digital-specific rules produce practical ambiguities. This study uses a qualitative exploratory design and thematic synthesis of peer-reviewed studies, regulatory documents and industry reports, applying the Transparency–Accountability–Authenticity (TAA) analytical framework and a framework-method (deductive–inductive) coding strategy. Findings show frequent absence of clear disclosure in unbranded disease-awareness and influencer content, amplified reach via algorithmic targeting, and fragmented regulatory responses. The TAA framework provides an operational lens to guide policy reform, platform accountability, and future empirical evaluation.

Keywords: *Pharmaceutical Marketing, Consumer Behavior, Drug Promotion, Healthcare Communication, Regulatory Challenges, Digital Marketing in Pharma, Brand Perception, Ethical Marketing.*

How to Cite: Deepshikha Singh (2025) The Impact of Digital Strategies on Pharmaceutical Marketing Consumer Behavior, Ethics, and Compliance. *International Journal of Innovative Science and Research Technology*, 10(11), 2379-2387. https://doi.org/10.38124/ijisrt/25nov1009

I. INTRODUCTION

Pharmaceutical marketing has become one of the most closely scrutinised health communication because it has a direct effect on how patients respond, how doctors prescribe drugs, and how much people trust healthcare institutions. The stakes are different from marketing consumer goods: marketing methods can change how drugs are used, how people think about risk and effectiveness, and, ultimately impact population health outcomes (Ventola 2011; Liang and Mackey 2020). The conflict between business needs and moral obligations is stronger in this field than in most others. Traditionally, pharmaceutical marketing relied heavily on physician-oriented detailing and medical conferences, with limited direct visibility to patients (Sillup and Porth 2008). The digital transformation of healthcare communication has radically changed the ways that companies reach out to people. They can now target both prescribers and patients in ways that mix education, promotion, and persuasion (Almeman 2024).

Social media, online health forums, search engine optimization, and the increased use of patient-centered apps and portals have all helped the change to digital pharmaceutical marketing (Mackey, Li, and Liang 2020). Direct-to-consumer advertising (DTCA), previously limited to the United States and New Zealand, now includes digital counterparts that reach patients worldwide via social networks and cross-border platforms (Fugh-Berman and Ahari 2007; DeFrank et al. 2020). The empirical literature illustrates that these marketing methods profoundly influence patient requests and prescribing behaviors. For example, patients who see internet medicine ads are more likely to ask for certain drugs, which can affect what doctors decide to do, even if other options would be better for the patient (Franquiz and Stafford 2020). These dynamics provoke significant inquiries on the equilibrium between informed choice, consumer autonomy, and the implicit coercion embedded in persuasive marketing.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25nov1009

Ethical and regulatory considerations are particularly acute in this environment. The World Health Organization (WHO) has long known about the dangers of inappropriate advertising and has recommended for strict control of pharmaceutical ads (WHO 2020). The Food and Drug Administration (FDA) in the United States gives clear instructions on how to include risk-benefit information in marketing materials (FDA 2023). The European Union prohibits DTCA of prescription drugs altogether, though enforcement challenges remain as firms exploit digital loopholes (Morris and Clarkson 2019). In India, regulatory authorities like the Central Drugs Standard Control Organisation (CDSCO) and the Advertising Standards Council of India (ASCI) have made rules, but experts say that enforcement is weak and not well-suited for digital settings (Bhave 2019; Nagappan 2024).

The research gap exists at the convergence of digital revolution, customer trust, and regulatory control. While a substantial amount of research has investigated conventional pharmaceutical marketing and physician-centric promotion, there exists a paucity of studies that have thoroughly evaluated the ethical dilemmas unique to digital platforms (Johns 2025). New studies show that digital campaigns can lead to problems with false information, data privacy violations, and conflicts of interest (Mackey and Cuomo 2020). There is still not much of a synthesis of these findings into a single ethical framework that may help both policymakers and people in the industry. *To address this gap, this paper proposes the Transparency–Accountability–Authenticity (TAA) analytical framework — an operational lens that organises digital marketing as inputs (channels and tactics) → mediators (disclosure, targeting algorithms, framing) → outcomes (trust, patient requests, misinformation), with contextual moderators such as regulatory strength and platform affordances***.** There is a necessity to investigate the integration of trust-building mechanisms, such as openness, accountability, and authenticity, into digital pharmaceutical marketing tactics without compromising innovation and competition.

The objectives of this study are therefore twofold. First, it seeks to examine the role of pharmaceutical marketing in influencing consumer perception and decision-making, with special emphasis on digital platforms. Second, it aims to assess the regulatory and ethical challenges inherent in these practices, drawing on comparative insights from different jurisdictions. *Methodologically, the paper adopts a qualitative and exploratory design, applying the TAA analytical framework and using a framework-method (deductive–inductive) thematic synthesis of secondary sources including articles, regulatory documents, and industry reports to identify recurring patterns and interpretive mechanisms***.** A thematic analysis approach is employed to identify recurring patterns, contradictions, and opportunities across the literature. By pursuing these purposes, the study contributes to the broader discussion on how healthcare communication may be made both successful and ethically justified. In addition to their academic significance, the findings aim to influence policy discussions, aid regulators in developing effective guidelines, and support pharmaceutical companies in aligning their marketing strategies with compliance requirements and patient-centered principles.

II. LITERATURE REVIEW

The contemporary arena of pharmaceutical marketing is undergoing a paradigm shift with the increasing digitalization of healthcare communication. This transformation has intensified ethical, regulatory, and behavioral complexities, particularly as promotional practices increasingly rely on algorithmic targeting, influencer marketing, and data-driven personalization. To explore these dynamics, this study integrates theoretical, conceptual, and analytical perspectives that collectively explain how digital pharmaceutical marketing influences consumer behavior and ethical accountability.

At the theoretical level, the Elaboration Likelihood Model (ELM) (Petty & Cacioppo, 1986) provides a behavioral lens to understand how consumers process persuasive health messages through either central or peripheral routes of cognition. The degree of message scrutiny—driven by factors such as credibility, emotional appeal, and perceived authenticity—directly affects decision-making and trust formation in healthcare consumption.

Complementing this, the Institutional Theory (DiMaggio & Powell, 1983) offers a systemic perspective, elucidating how pharmaceutical marketing practices are shaped by broader institutional environments comprising legal norms, ethical standards, and regulatory enforcement capacities. Together, these theories bridge the micro-level psychological mechanisms of persuasion with the macro-level structures governing industry conduct.

Building on these theoretical foundations, the study employs the Transparency–Accountability–Authenticity (TAA) Framework as its analytical model. The TAA framework operationalizes key ethical constructs identified in existing literature and maps them to behavioral and institutional variables influencing digital marketing practices. By synthesizing insights from ELM and Institutional Theory, the TAA framework provides a multilevel analytical structure that connects individual cognitive responses, organizational ethical practices, and regulatory systems.

This integrative approach enables the study to critically assess how transparency and authenticity in digital communication influence consumer trust and how institutional accountability mediates the ethical boundaries of pharmaceutical marketing

- *The Elaboration Likelihood Model (ELM)*

Petty & Cacioppo, 1986; Shahab, Ghazali & Mohtar, 2021; Susmann et al., 2022 explains how individuals process persuasive messages through two cognitive routes: the central route, which involves thoughtful evaluation of message content, and the peripheral route, which relies on emotional cues, imagery, or perceived credibility of the source. In the context of digital pharmaceutical marketing, contemporary

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25nov1009

strategies such as influencer endorsements, short-form health videos, and algorithm-driven promotional content often stimulate peripheral processing. This can increase consumer susceptibility to persuasion without critical evaluation of medical accuracy or evidence. Recent studies (Shahab et al., 2021; Susmann et al., 2022) emphasise that fostering transparency, accountability, and authenticity in communication helps shift audience engagement toward the central route, encouraging more informed and responsible health-related decision-making.

At a systemic level, Institutional Theory (DiMaggio & Powell, 1983; Eriksson, Levin & Nedlund, 2021) offers a structural lens to interpret regulatory and ethical diversity across global pharmaceutical markets. It posits that marketing practices are shaped by institutional environments comprising legal mandates, professional norms, and enforcement capacities. Consequently, variations between the U.S., E.U., and Indian pharmaceutical marketing frameworks can be viewed as reflections of distinct institutional logics—ranging from compliance-driven to value-based governance models. Integrating ELM and Institutional Theory thus provides a multilevel analytical perspective that connects individual persuasion dynamics with systemic ethical governance, enhancing understanding of how digital pharmaceutical marketing operates within both psychological and institutional domains.

- *Pharmaceutical Marketing and Consumer Behaviour*

Pharmaceutical marketing uniquely influences customer behavior due to the asymmetric information structure inherent in healthcare. Patients frequently lack the technical proficiency to independently assess medications, rendering them especially vulnerable to marketing influences (Ventola 2011). Numerous studies have examined direct-to-consumer advertising (DTCA) for its efficacy in enhancing brand recognition, augmenting patient demand for specific medications, and even elevating diagnostic rates for particular diseases (Franquiz and Stafford 2020). Proponents contend that DTCA fosters patient empowerment and adherence to therapy, but critics underscore the potential for improper prescribing and increased costs (Donohue et al. 2007). Empirical evidence indicates that marketing exposure alters patient-physician interactions: doctors may feel compelled to fulfill requests influenced by advertising, even when alternatives are clinically valid (DeFrank et al. 2020). This body of evidence was used to inform the Transparency–Accountability–Authenticity (TAA) analytical framework employed in this study, linking observed marketing effects to the mediators and outcomes represented in the framework.

- *Digital Marketing in Pharm*

The digitalization of healthcare communication has transformed the extent and magnitude of pharmaceutical marketing. Social media sites let you talk to patients in real time, and search engine optimization and algorithmic targeting make ads more relevant to each person (Mackey, Li, and Liang 2020). Mobile health (mHealth) apps and patient portals have added to the pharmaceutical industry's digital ecology, making it possible for people to stay in touch with their doctors even when they are not seeing them (Almeman 2024).

But digital media also make it hard to tell the difference between education and advertising. For example, unbranded disease awareness initiatives on social media are often connected to certain medicine brands in a roundabout way, which makes them seem like they are just giving information (Fugh-Berman and Ahari 2007). The emergence of "health influencers" has introduced an additional layer of complexity: sponsored information is often integrated into ostensibly genuine narratives, complicating regulatory supervision (Johns 2025). For analytic transparency, findings from studies of unbranded disease-awareness campaigns and influencer marketing were systematically mapped to the TAA constructs (transparency, accountability, authenticity) during coding. Digital marketing across borders is another problem. It is hard to police national rules when platforms like Facebook, YouTube, and Instagram share content all over the world. Consequently, patients in places where direct-to-consumer advertising of prescription medications is forbidden, such as the European Union, are nonetheless subjected to advertising from other areas (Morris and Clarkson 2019).

- *Regulatory and Ethical Challenges*

Regulation of pharmaceutical marketing is highly fragmented, reflecting varied policy approaches among jurisdictions. The FDA enforces tight disclosure rules for DTCA of prescription medications in the United States. These rules stress the importance of presenting both risks and benefits in a balanced way (FDA 2023). Empirical assessments reveal that adherence to these norms is inconsistent, especially in digital environments where spatial limitations hinder the dissemination of risk information (Faerber and Kreling 2014). In contrast, Directive 2001/83/EC of the European Union completely bans DTCA of prescription pharmaceuticals. It only allows communication aimed at healthcare professionals and limited disease awareness programs. However, the global reach of digital platforms makes enforcement difficult (Morris and Clarkson 2019). The Drugs and Magic Remedies (Objectionable Advertisements) Act of 1954 and CDSCO guidelines in India theoretically make deceptive advertising illegal, but researchers say that enforcement is inadequate, especially for internet media (Bhave 2019; Nagappan 2024). The literature highlights persistent challenges such as the manipulation of vulnerable people, the promotion of off-label uses, and the exploitation of health worries (Mackey and Cuomo 2020). Patient privacy has become an urgent issue, since digital campaigns increasingly depend on health data analytics and behavioral profiling (Liang and Mackey 2020). The ethical discourse transcends conventional promotional limits, encompassing data governance, algorithmic transparency, and the safeguarding of consumer autonomy. Wherever possible, comparative regulatory studies were synthesised using a framework-based approach to assess how disclosure requirements, enforcement capacity and platform governance act as contextual moderators within the TAA model.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25nov1009

➢ *Brand Perception and Trust*

Trust is both a result and a factor that affects how well pharmaceutical marketing works. Studies regularly show that clear, patient-centered communication improves brand perception and makes patients more likely to stick with their treatment (Morgenson et al. 2019). Conversely, exposure of unethical practices, such as suppression of adverse trial data or aggressive promotion of opioids, has eroded trust in pharmaceutical companies globally (Van Zee 2009).

Digital marketing changes how people trust each other. Online engagement lets businesses make their brands more human and build interactive ties with patients (Nagappan 2024). Conversely, the widespread dissemination of misinformation and the apparent manipulation via digital platforms provide a significant risk of exacerbating public skepticism (Mackey, Li, and Liang 2020). Researchers contend that customer confidence in pharmaceutical companies depends not solely on adherence to regulations but also on the voluntary embrace of ethical principles that beyond basic legal obligations (Johns 2025).

An increasing corpus of literature advocates for the establishment of an ethical framework grounded in transparency, accountability, and authenticity. This kind of system would need explicit labels on ads, full disclosure of any conflicts of interest, and steps taken to stop false information from spreading. It is crucial to maintain trust not only at the individual brand level but throughout the pharmaceutical sector, as reputational crises in one company frequently affect opinions of the entire industry (Fugh-Berman and Ahari 2007). Several authors therefore call for operational ethical frameworks; this study responds by proposing the TAA framework and applying a framework-method thematic synthesis to link these normative proposals to empirical evidence.

III. METHODOLOGY

This study utilizes a qualitative, exploratory research approach, a decision that underscores the intricacy of pharmaceutical marketing as both a business and ethical phenomena. Quantitative methods, although useful for assessing outcomes like sales or prescription rates, fail to adequately capture the intricate relationship among regulation, ethics, and consumer trust. In contrast, qualitative inquiry facilitates a more profound analysis of the construction, contestation, and regulation of marketing practices within academic discourse and policy frameworks (Creswell and Poth 2018). Exploratory designs are especially appropriate for areas that lack robust theoretical frameworks, such as digital pharmaceutical marketing, where normative frameworks are still developing (Stebbins 2001). To make the analytic reasoning explicit and reproducible, this study applies the Transparency–Accountability–Authenticity (TAA) analytical framework and implements a framework-method (deductive–inductive) thematic synthesis so that conceptual claims are tied directly to coded evidence.

The study is based solely on secondary data obtained from peer-reviewed journals, regulatory documents, and industry reports. Systematic searches of peer-reviewed literature using keywords including pharmaceutical marketing, digital promotion, direct-to-consumer advertising, healthcare communication, regulatory issues, and ethical frameworks helped find sources. Grey literature was excluded unless generated by reputable organizations such as the World Health Organization, the International Federation of Pharmaceutical Manufacturers and Associations, or national regulatory bodies including the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and India's Central Drugs Standard Control Organisation (CDSCO). Searches were conducted across major bibliographic sources and authoritative regulatory websites and supplemented by reference chaining from included papers; selection prioritised relevance to digital promotion, regulatory text, and empirical evidence of consumer/prescriber impact.

Data were analysed using thematic analysis, which allows for systematic identification of recurring patterns, tensions, and conceptual linkages across diverse sources (Braun and Clarke 2006). Themes were inductively derived and broadly organised around consumer behaviour, digital transformation, regulatory frameworks, and brand trust. A comparative lens was applied to highlight jurisdictional differences, such as the permissive but highly regulated environment of the United States, the restrictive stance of the European Union, and the fragmented enforcement context of India. Analytically, we combined inductive theme-finding with a deductive coding frame based on the TAA constructs: (1) Transparency (disclosure practices and labeling), (2) Accountability (platform and industry governance, enforcement), and (3) Authenticity (patient-centredness and truthful communication). Coding followed the Framework Method (familiarisation → developing initial framework → indexing → charting → mapping & interpretation) and produced a source-by-code matrix and a short codebook (see Table 1 and Appendix A for the codebook and example matrix).

The research is theoretically based on ethical marketing theory and consumer behavior theory. The first one sets standards based on fairness, openness, and protecting the health of consumers (Murphy, Laczniak, and Prothero 2012). The second one shows how structural information gaps in healthcare make patients very responsive to marketing cues (Akerlof 1970; Ventola 2011). The TAA framework is positioned as an operational bridge between these theoretical traditions and empirical findings, enabling the mapping of marketing inputs → mediators → outcomes under different regulatory moderators.

The limitations of this approach must also be acknowledged. Because the study relies on secondary data, findings remain contingent upon the quality, scope, and representativeness of existing research. Regulatory documents, while authoritative, may reflect aspirational policies rather than enforcement realities, particularly in low- and middle-income countries. Furthermore, thematic analysis is interpretive by nature and therefore open to researcher bias (Nowell et al. 2017).

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25nov1009

These limitations were mitigated through triangulation across source types, critical reflexivity during coding, maintenance of an audit trail, and cross-checking of key codes by a second reviewer where possible. These limitations are mitigated through triangulation of multiple data sources, cross-jurisdictional comparison, and critical reflexivity throughout the research process.

Table 1 Thematic Analysis of Literature on Pharmaceutical Marketing and Patient Welfare

Theme	Sub-theme	Sources	Key Insights	Jurisdictional Insights
Consumer Behavior	Influence of Direct-to-Consumer (DTC) Advertising	Mintzes (2012); Donohue et al. (2007); WHO Guidelines (2009)	DTC advertising impacts patient demand, sometimes leading to over-prescription; mixed evidence on informed decision-making	Strongly regulated in EU; Permitted in USA with disclosure requirements; In India, DTCA largely restricted but digital loopholes exist
Digital Transformation	Rise of e-pharmacies and telemedicine marketing	Ghosh (2020); Indian IT Act; FDA Guidance on Social Media (2014)	Shift from traditional reps to online campaigns; algorithm-driven targeting raises privacy and misinformation concerns	India: Draft e-Pharmacy Rules (2018) pending; USA: FDA monitors online drug promotion; EU: GDPR imposes data-use restrictions
Regulatory Frameworks	Comparative regulation of pharma marketing	Drugs & Magic Remedies (Objectionable Advertisements) Act, 1954; US FDA Regulations; EU Directives	Regulatory inconsistencies affect global campaigns; India's outdated law fails to cover digital media adequately	India relies on self-regulation (e.g., UCPMP) with weak enforcement
Brand Trust & Ethics	Corporate social responsibility and patient-centricity	Foucault (Biopolitics); Kim (2021); ICMR Ethical Guidelines	Ethical lapses (misleading claims, opaque pricing) erode trust; patient-centric models increase compliance and long-term brand loyalty	India: Growing litigation under CPA 2019; USA: class actions for deceptive advertising; EU: emphasis on proportionality and consumer rights

IV. DISCUSSION

The outcomes of this study highlight that pharmaceutical marketing in the digital age is both a commercial opportunity for companies and a significant ethical and regulatory challenge for healthcare systems. The thematic analysis of existing literature uncovers persistent tensions between consumer autonomy and corporate influence, the globalization of promotional channels and national regulatory frameworks, and the short-term commercial benefits of aggressive promotion versus the long-term necessity of maintaining trust in healthcare.

- *Analytical Framework (TAA)*

The integration of the Transparency–Accountability–Authenticity (TAA) framework with the Elaboration Likelihood Model (ELM) and Institutional Theory provides a powerful composite lens for understanding the ethical and behavioral dimensions of digital pharmaceutical marketing. Each of these models captures a distinct layer of analysis as TAA highlights the ethical structure of communication, ELM elucidates how persuasion operates at the cognitive level, and Institutional Theory situates these micro and meso-level processes within broader regulatory and cultural systems.

The TAA model is built upon four interlinked components: inputs, mediators, outcomes, and contextual moderators. Inputs encompass the digital marketing artefacts that constitute the communicative field; social media campaigns, unbranded disease-awareness initiatives, influencer collaborations, search engine optimization, and mobile health communications. Mediators represent the mechanisms through which these inputs exert influence, including visibility of disclosures, algorithmic personalization, narrative framing, and the emotional tone of messages. Outcomes capture the behavioral and perceptual consequences, such as shifts in patient trust, prescribing behavior, or the circulation of misinformation. Contextual moderators such as regulatory strength, enforcement capacity, platform affordances, and patient vulnerability; shape how these relationships unfold across jurisdictions. The analytical value of the TAA model lies in its flexibility: it accommodates both deductive codes derived from its three ethical pillars and inductive codes emerging from contextual data, thereby combining conceptual rigor with empirical responsiveness.

When examined through the lens of the Elaboration Likelihood Model, the transparency dimension of TAA corresponds to the central route of persuasion, where consumers engage in deeper cognitive processing based on evidentiary reasoning and explicit disclosures. Authenticity aligns with the peripheral route, where attitudes are shaped by heuristic cues such as emotional resonance, influencer

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25nov1009

credibility, or perceived social proof. In the digital pharmaceutical context, these two routes interact continuously. When transparency is high and disclosures are clear, consumers may process information critically; when disclosures are ambiguous or obscured, peripheral cues dominate, heightening susceptibility to brand-driven persuasion.

Institutional Theory expands this analysis by embedding these persuasion mechanisms within a broader regulatory and normative framework. Accountability, as articulated in the TAA model, reflects how institutional pressures govern firm behavior in digital spaces. In jurisdictions with stringent regulatory oversight, such as the European Union, institutional constraints limit direct-to-consumer (DTC) pharmaceutical advertising through explicit bans under Directive 2001/83/EC. In contrast, the United States permits DTC advertising under Food and Drug Administration (FDA) supervision, focusing on balanced disclosure of risks and benefits. Empirical assessments, however, reveal that digital ads often underrepresent risks, particularly when embedded in influencer content or algorithmically targeted streams (Faerber and Kreling 2014; FDA 2023). In emerging markets such as India, regulatory regimes exist; the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, and the Uniform Code for Pharmaceuticals Marketing Practices (UCPMP) but enforcement remains inconsistent, especially online (Bhave 2019; Nagappan 2024). Thus, institutional robustness mediates the extent to which accountability is operationalized in practice.

Secondary data provide quantitative grounding to these theoretical intersections. In 2020, the median promotional expenditure for the 150 top-selling U.S. prescription drugs was estimated at $20.9 million, with direct-to-consumer advertising comprising approximately 13.5 percent of this total (DiStefano et al. 2023). Although these figures represent a small fraction of total sales, they illustrate how promotional spending at scale can influence both clinical interactions and patient decision-making. Empirical studies confirm that patients exposed to such advertising are more likely to request specific branded prescriptions, a pattern that can enhance dialogue but may also pressure clinicians toward unnecessary or suboptimal prescribing (DeFrank et al. 2020; Franquiz and Stafford 2020). Parallel data from India's Advertising Standards Council of India (ASCI) reveal a similar dynamic at a different scale: in its 2023–24 report, digital ads accounted for roughly 85 percent of total complaints, with the healthcare sector responsible for the highest proportion of violations. Digital compliance rates stood at approximately 75 percent, notably lower than those observed in print and television media, underscoring the transparency and accountability gaps that the TAA model seeks to identify (ASCI 2024).

These data demonstrate how institutional variations and technological affordances shape the balance between persuasion and ethics. Under ELM, algorithmic personalization functions as a mediator that enhances peripheral processing by delivering emotionally resonant, tailored messages. Within TAA, this same mechanism appears as a transparency deficit and an accountability risk. Institutional Theory explains the persistence of such patterns: platforms operate under transnational logics where jurisdictional enforcement is fragmented, allowing cross-border promotional spillover. Hence, the triadic model reveals how weak institutional constraints amplify the persuasive power of digital marketing through both cognitive and ethical pathways.

The interpretive synergy of these frameworks suggests several theoretical insights. First, the transparency deficits observable in digital contexts often coincide with increased peripheral-route persuasion, producing stronger but less informed attitudinal changes. Second, accountability lapses correlate with institutional weakness, where fragmented oversight enables exploitative marketing tactics that mimic authenticity. Third, authenticity tensions emerge when patient-centered narratives are strategically simulated to enhance persuasion while lacking genuine ethical commitment. These findings collectively advance the understanding of how ethical failures in digital pharmaceutical marketing are not isolated micro-level events but systemic outcomes of misaligned cognitive, communicative, and institutional structures.

Digitalization has magnified both the reach and opacity of pharmaceutical promotion. As global promotional spending migrates from traditional media to algorithmically curated platforms the risks of misinformation, exploitative targeting, and erosion of trust intensify. Yet, when transparency and authenticity are institutionally reinforced, digital communication can foster patient empowerment and improve adherence. Disease-awareness campaigns, when clearly disclosed, have demonstrated positive effects on diagnostic rates and health literacy (Ventola 2011). Mobile health applications and online patient communities can enhance pharmacovigilance through real-time feedback loops (Almeman 2024). These examples affirm that the digital medium is not inherently unethical; rather, its outcomes depend on how institutional accountability interacts with the cognitive dynamics of persuasion.

Table 2 Operationalizing TAA: Indicators and Policy Levers

Pillar	Operational indicators (what to code/measure)	Practical interventions / policy levers	Primary actors
Transparency	Presence/absence of explicit disclosure labels; clarity of sponsored content; accessibility of risk information	Mandatory uniform disclosure formats; prominence rules for risk statements; influencer sponsorship registries	Regulators, Platforms, Industry
Accountability	Evidence of platform moderation; complaint resolution records; enforcement actions & penalties	Platform reporting requirements; regulatory audit powers; industry adjudication panels	Platforms, Regulators, Industry bodies

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25nov1009

Authenticity	Patient-centred language; alignment of claims with evidence; absence of sensationalist framing	Certification for patient-centred campaigns; pre-approval for high-risk messaging; incentives for evidence-based education	Industry, Professional bodies, Regulators

A key contribution of this study is to synthesise these findings into the contours of an ethical framework for digital pharmaceutical marketing. The framework would rest on three pillars. First, transparency, requiring clear disclosure of promotional intent in all digital content, including influencer-driven and algorithmically targeted advertisements. Second, accountability, ensuring that firms assume responsibility for the downstream effects of their campaigns, including unintended consequences such as misinformation or misuse. Third, authenticity, encouraging communication strategies that prioritize patient welfare, accurate risk–benefit presentation, and alignment with public health objectives. These principles extend beyond compliance, reflecting a broader responsibility of the pharmaceutical sector to operate as a socially legitimate actor in healthcare ecosystems.



Fig 1 TAA Framework

V. CONCLUSION AND FUTURE RESEARCH DIRECTIONS

This study has examined the intricate dynamics of pharmaceutical marketing in the digital age, evaluating its ethical dilemmas, regulatory obstacles, and effects on consumer behavior. The results show that marketing has changed from traditional ads aimed at doctors to very advanced digital methods that reach patients directly. Such technologies can make health information more accessible and give customers more power, but they also make it harder to tell the difference between education and persuasion, which raises questions about transparency and making educated choices.

Using the Transparency–Accountability–Authenticity (TAA) analytical framework, we mapped how specific digital inputs (social media, influencer posts, SEO, mHealth) operate through mediators (disclosure practices, algorithmic targeting, framing) to produce measurable outcomes (patient requests, prescribing shifts, changes in trust, and misinformation). Applying TAA shows where interventions are most likely to interrupt harmful chains (for example, standardised disclosure reduces ambiguity at the mediator level and lowers request-driven prescribing at the outcome level).

Comparative analysis indicates that regulatory frameworks continue to be disjointed. The United States has standards that are based on disclosure, but it gets a lot of flak for the huge impact of direct-to-consumer advertising. The European Union takes a strict stance against commercializing health communication, but India shows inadequate enforcement and unclear rules. None of these approaches effectively addresses the complexities of digital promotion, especially in global online environments where jurisdictional boundaries are fluid. A common subject is how easy it is to lose trust in pharmaceutical marketing. Historical disputes against deceptive advertising have fostered skepticism, and new digital tactics may intensify these apprehensions. To restore trust, companies need to use ethical marketing frameworks based on honesty, accuracy, and patient care. They also need more flexible and coordinated worldwide rules.

Regulators should prioritise (a) uniform disclosure formats for digital health promotion, (b) platform-level ad transparency (public ad libraries and audit trails), and (c)

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25nov1009

clearer accountability mechanisms (timely enforcement, cross-border cooperation). Industry actors should adopt voluntary authenticity standards (evidence-aligned messaging, clear sponsorship disclosure) while platforms should enable enforcement by improving ad metadata and complaint handling. Limitations are that as a secondary-data, exploratory synthesis the findings depend on existing literature and regulatory texts; empirical effect sizes and causal claims require primary data. Variation in study designs and uneven reporting across jurisdictions constrained quantitative comparison.

Future research should move from description to rigorous, actionable evaluation. Large-scale content analyses can quantify the prevalence of TRANSPARENCY_ABSENT and INFLUENCER_SPONSORED content across platforms and jurisdictions; natural or quasi-experimental studies can exploit policy changes or platform interventions to estimate causal effects of disclosure rules on patient requests and prescribing; controlled experiments (lab or vignette designs) can test how different disclosure formats and authenticity cues affect patient comprehension, trust and intention to request medicines; in-depth qualitative ethnographies and user studies with patients and clinicians can reveal how digital promotions are interpreted in real clinical encounters; implementation research should pilot and evaluate platform-level tools (public ad libraries, audit dashboards, influencer registries) and cross-border enforcement models; and finally, metric development work must create and validate evaluative indicators for ethical digital marketing (for example, sponsorship prevalence, complaint-resolution latency, and changes in request-to-prescription ratios). Together these approaches will empirically validate and refine the TAA framework and inform evidence-based regulatory and platform design.

REFERENCES

[1]. Akerlof, G.A., 1970. The market for ‘lemons’: Quality uncertainty and the market mechanism. *Quarterly Journal of Economics*, 84(3), pp.488–500.

[2]. Braun, V. & Clarke, V., 2006. Using thematic analysis in psychology. *Qualitative Research in Psychology*, 3(2), pp.77–101.

[3]. Creswell, J.W. & Poth, C.N., 2018. *Qualitative inquiry and research design: Choosing among five approaches*. 4th ed. Sage Publications.

[4]. DeFrank, J.T., Berkman, N.D., Kahwati, L.C., Cullen, K.E., Woolf, S.H. & Brewer, N.T., 2020. Direct-to-consumer advertising of prescription drugs and the patient–prescriber encounter: A systematic review. *Health Communication*.

[5]. DiStefano, M., Markell, J., Doherty, C., Alexander, G.C. & Anderson, G., 2023. Spending on consumer advertising for top-selling prescription drugs in US favors those with low added benefit. *Johns Hopkins Bloomberg School Study*.

[6]. Donohue, J.M., Cevasco, M. & Rosenthal, M.B., 2007. A decade of direct-to-consumer advertising of prescription drugs. *New England Journal of Medicine*, 357(7), pp.673–681.

[7]. Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. Government of India.

[8]. Drugs and Cosmetics Act, 1940. Government of India.

[9]. FDA, 2023. *Guidance for industry: Direct-to-consumer prescription drug advertisements*. U.S. Food and Drug Administration.

[10]. Franquiz, M.J., Shrank, W.H., Ettner, S.L. & Mangione, C.M., 2021. Direct-to-consumer drug advertisement and prescribing practices: Evidence review and practical guidance for clinicians. *Journal of General Internal Medicine*.

[11]. Fugh-Berman, A. & Ahari, S., 2007. ‘Influence of industry’ and its implications for public health. *PLoS Medicine*, 4(4), e83.

[12]. Gibson, S., 2014. As more consumers turn to the internet for health information: Challenges for healthcare providers. *International Journal of Health Policy and Management*.

[13]. Liang, B.A. & Mackey, T.K., 2010. Reforming off-label promotion to enhance orphan disease treatment. *Science*, 327(5963), pp.273–274.

[14]. Mackey, T.K., Li, J. & Liang, B.A., 2020. Direct-to-consumer advertising with interactive internet media: Global regulation and public health issues. *JAMA*.

[15]. Medical Council of India, 2002. *Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations*. New Delhi: Medical Council of India.

[16]. Murphy, P.E., Laczniak, G.R. & Prothero, A., 2012. Ethical marketing: Guidelines, practices, and consumer trust. *Journal of Business Ethics*, 105(2), pp.157–170.

[17]. Nowell, L.S., Norris, J.M., White, D.E. & Moules, N.J., 2017. Thematic analysis: Striving to meet the trustworthiness criteria. *International Journal of Qualitative Methods*, 16, pp.1–13.

[18]. Stebbins, R.A., 2001. *Exploratory research in the social sciences*. Sage Publications.

[19]. The Consumer Protection Act, 2019. Government of India.

[20]. The Uniform Code of Pharmaceutical Marketing Practices (UCPMP), 2014. Department of Pharmaceuticals, Government of India.

[21]. Ventola, C.L., 2011. Direct-to-consumer pharmaceutical advertising: Therapeutic or toxic? *P & T*, 36(10), pp.669–684.

[22]. WHO, 2020. *Ethical criteria for medicinal drug promotion*. World Health Organization.

[23]. Eriksson, T., Levin, L-Å. and Nedlund, A-C. (2021) ‘Centrality and compatibility of institutional logics when introducing value-based reimbursement’, *Journal of Health Organization and Management*, 35(9), pp. 298-314.

[24]. Petty, R.E. and Cacioppo, J.T. (1986) *Communication and persuasion: Central and peripheral routes to attitude change.* New York: Springer-Verlag.

[25]. Shahab, M.H., Ghazali, E. and Mohtar, M. (2021) ‘The role of elaboration likelihood model in consumer behaviour research and its extension to new technologies: A review and future research agenda’, *International Journal of Consumer Studies*, 45(4), pp. 664-689.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25nov1009

[26]. Susmann, M.W., Luttrell, A., and Petty, R.E. (2022) 'Persuasion amidst a pandemic: Insights from the Elaboration Likelihood Model', *European Review of Social Psychology*, 33(2), pp. 323-359.
[27]. DiMaggio, P.J. and Powell, W.W. (1983) 'The iron cage revisited: Institutional isomorphism and collective rationality in organizational fields', *American Sociological Review*, 48(2), pp. 147-160.